Johnson & Johnson (JNJ) beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara....
The short answer: More than many of its peers, at least in terms of yield.
These three stocks boast an average yield that is more than three times the average dividend payer in the benchmark S&P 500 index.
They don't have the most exciting businesses, but they have a lot to offer nonetheless.
Strong revenue growth and product innovations have Wall Street believing that this growth stock will rally 114% over the next 12 months.
Looking for value? These 3 dividend aristocrats are cheap compared with their industry peers.
/CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and...
/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.
/CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes...
/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences has recently underperformed the Healthcare sector, but Wall Street analysts anticipate a modest upside for the stock.